Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
CATALYST BIOSCIE RG (NQ: CBIO)
23.64 USD  UNCHANGED
Official Closing Price  /  Updated: 8:00 PM EDT, May 24, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 228,382
Open 24.81
Bid (Size) 22.62 (100)
Ask (Size) 25.95 (100)
Prev. Close 23.64
Today's Range 23.51 - 24.81
52wk Range 3.110 - 36.50
Shares Outstanding 11,935,169
Dividend Yield N/A
Performance
YTD
+64.51%
+64.51%
1 Month
-11.23%
-11.23%
3 Month
-10.96%
-10.96%
6 Month
+260.92%
+260.92%
1 Year
+482.27%
+482.27%
Top News
More News
New Research Coverage Highlights BlackRock Capital Investment, Tootsie Roll Industries, Catalyst Biosciences, Macerich, Quotient Technology, and PennyMac Mortgage Investment Trust — Consolidated Reven
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BlackRock Capital... Read More
from GlobeNewswire News Releases
Catalyst Biosciences Announces Oral Presentation at the World Federation of Hemophilia 2018 World Congress
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced an oral presentation of... Read More
from GlobeNewswire News Releases
More News
Read More
Catalyst Biosciences to Host Key Opinion Leader Meeting on Novel Treatments for Hemophilia B and Hemophilia with Inhibitors
from GlobeNewswire News Releases
Catalyst Biosciences Reports First Quarter Operating & Financial Results and Provides Corporate Update
from GlobeNewswire News Releases
Catalyst Biosciences Announces Presentation at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting
from GlobeNewswire News Releases
Pre-Market Technical Scan on Biotech Equities -- Cara Therapeutics, Catabasis Pharma, Catalyst Biosciences, and Celgene
from PR Newswire
Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
from GlobeNewswire News Releases
Analysis: Positioning to Benefit within Catalyst Biosciences, CorEnergy Infrastructure Trust, PennyMac Mortgage Investment Trust, Raven Industries, Acacia Communications, and Sandy Spring — Research H
from GlobeNewswire News Releases
Catalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) Asset
from GlobeNewswire News Releases
Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference
from GlobeNewswire News Releases
Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference
from GlobeNewswire News Releases
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial